Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis

被引:1
|
作者
Vidula, Mahesh K. [1 ]
Selvaraj, Senthil [1 ,5 ,6 ]
Rojulpote, Chaitanya [2 ]
Bhattaru, Abhijit [2 ]
Kc, Wumesh [1 ]
Hansbury, Mary [2 ]
Schubert, Erin [2 ]
Clancy, Caitlin B. [3 ]
Rossman, Milton [3 ]
Goldberg, Lee R. [1 ]
Farwell, Michael [2 ]
Pryma, Daniel [2 ]
Bravo, Paco E. [1 ,2 ,4 ]
机构
[1] Univ Penn, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA USA
[3] Univ Penn, Dept Med, Div Pulm Med, Philadelphia, PA USA
[4] Univ Penn, Dept Radiol, Div Cardiothorac Imaging, Philadelphia, PA USA
[5] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC USA
[6] Duke Mol Physiol Inst, Durham, NC USA
关键词
blood glucose; fasting; inflammation; outpatient; sarcoidosis;
D O I
10.1161/CIRCIMAGING.124.016774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Fluorine-18 fluorodeoxyglucose (FDG) with positron emission tomography (PET) is the standard for detecting myocardial inflammation in cardiac sarcoidosis, requiring preparation with the ketogenic diet (KD) to achieve myocardial glucose suppression. Despite this, incomplete myocardial glucose suppression remains a significant issue, and strategies to reduce myocardial glucose uptake (MGU) and identify incomplete myocardial glucose suppression are required. This study sought to understand the relationship between point-of-care beta-hydroxybutyrate (BHB) and different patterns of MGU and between KD and fasting duration with MGU in patients undergoing evaluation for cardiac sarcoidosis. METHODS: We prospectively included 471 outpatients who underwent FDG-PET for cardiac sarcoidosis evaluation, followed the KD for 1 (n=100), 2 (n=29), and >= 3 days (n=342), fasted for at least 12 hours, and had BHB levels measured immediately before FDG injection. Images were classified as (1) no MGU (negative), (2) focal/multifocal (positive), (3) diffuse (nondiagnostic), or (4) nonspecific uptake (NS-MGU). RESULTS: Cardiac FDG-PET scans were interpreted as the following: 376 (79.83%) negative; 61 (12.95%) positive; 14 (2.97%) diffuse; and 20 (4.25%) NS-MGU. There was a strong negative relationship between BHB levels and MGU (P<0.0001). BHB levels increased significantly with KD duration (P<0.0001) and fasting time (P=0.0067). The combined rate of diffuse, NS-MGU, and positive scans (34%, 28%, 16%) decreased inversely with KD duration (1, 2, and >= 3 days, respectively). However, MGU was not different across different fasting times (P=0.6). Blood glucose levels were not associated with MGU (P=0.17) and only weakly associated with BHB levels (R-2=0.03; P<0.001). CONCLUSIONS: We observed a strong inverse relationship between ketosis and patterns of MGU. Longer KD and fasting durations are associated with higher ketosis. However, only KD duration was associated with lower rates of MGU. Measurement of BHB levels before FDG-PET using point-of-care testing is feasible and may facilitate the management of patients referred for myocardial inflammation.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Prognostic value of FDG uptake on pretreatmen PET/CT in patients with cardiac sarcoidosis
    Ishiyama, Mitsutomi
    Vesselle, Hubert
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [2] Evaluation of Clinical Variables Affecting Myocardial Glucose Uptake in Cardiac FDG PET
    Lee, Yeongjoo
    Jang, Jaehyuk
    Lim, Sungmin
    Na, Sae Jung
    DIAGNOSTICS, 2024, 14 (16)
  • [3] What Is the Optimal Method on Myocardial Suppression in FDG PET/CT Evaluation of Cardiac Sarcoidosis?
    Lu, Yang
    Sweiss, Nadera J.
    Macapinlac, Homer A.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (11) : 904 - 905
  • [4] Diagnosis and evaluation of cardiac sarcoidosis with FDG PET/CT and PET/MR
    Ng, Sze Jia
    Lau, Hui Chong
    Raynor, William
    Werner, Thomas
    Saboury, Babak
    Revheim, Mona-Elisabeth
    Alavi, Abass
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [5] The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis
    Azadeh Ahmadian
    Sumeet Pawar
    Praveen Govender
    Jeffrey Berman
    Frederick L. Ruberg
    Edward J. Miller
    Journal of Nuclear Cardiology, 2017, 24 : 413 - 424
  • [6] The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis
    Ahmadian, Azadeh
    Pawar, Sumeet
    Govender, Praveen
    Berman, Jeffrey
    Ruberg, Frederick L.
    Miller, Edward J.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (02) : 413 - 424
  • [7] Relationship Between Fasting Time on Ketogenic Diet and Myocardial Glucose Suppression in Patients Referred for Cardiac Sarcoidosis Evaluation on FDG-PET Imaging
    Bhattaru, Abhijit
    Vidula, Mahesh K.
    Selvaraj, Senthil
    Rojulpote, Chaitanya
    Bravo, Paco E.
    CIRCULATION, 2023, 148
  • [8] Development of a reproducible FDG PET/CT cardiac imaging protocol for the evaluation of cardiac sarcoidosis
    Kulm, Julie
    Mittra, Erik
    Guo, H. Henry
    Witteles, Ronald
    Quon, Andrew
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54
  • [9] Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
    Ahmadian, Azadeh
    Brogan, Ashley
    Berman, Jeffrey
    Sverdlov, Aaron L.
    Mercier, Gustavo
    Mazzini, Michael
    Govender, Praveen
    Ruberg, Frederick L.
    Miller, Edward J.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2014, 21 (05) : 925 - 939
  • [10] Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
    Azadeh Ahmadian
    Ashley Brogan
    Jeffrey Berman
    Aaron L. Sverdlov
    Gustavo Mercier
    Michael Mazzini
    Praveen Govender
    Frederick L. Ruberg
    Edward J. Miller
    Journal of Nuclear Cardiology, 2014, 21 : 925 - 939